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vención de manera oportuna aumentó en 11%. El costo por paciente sin EAG de
manera habitual fue de $16,981.77 mientras que con la intervención del farmacéu-
tico fue de $11,158.89. La razón costo efectividad incremental demostró que por
cada paciente adicional sin EAG el sistema de salud ahorra $40,405.18.
CONCLUSIONES: La inclusión del farmacéutico en el equipo de atención fue costo-
ahorradora.
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OBJECTIVES: The potential role of private health care providers and privatization
has been under heavy discussion in many countries. In the Hungarian health care,
there was a clearly supporting health policy regarding the increasing role of private
health care providers. The aim of the study is to analyze the market share of
for-profit private sector from the public health insurance expenditures on medical
services. METHODS: Data were derived from the nationwide administrative data-
set of the National Health Insurance Fund Administration (OEP), the only health
care financing agency in Hungary, covering the period 2006-2009. The analysis
includes the medical provisions (primary care, health visitors, dental care, out- and
inpatient care, home care, kidney dialysis, CT-MRI). We calculated the health in-
surance reimbursement according to the following categories of health care pro-
viders’ ownership status: local authorities, central government, for-profit compa-
nies and non-profit providers.RESULTS: In 2006 only 15.8% (112.8 billion Hungarian
Forint, HUF) of total expenditure for medical services went to for-profit private
providers, 53.9% to local authorities, 24.7% to central government and 5.6% to non-
profit sector. For 2009, the market share of private for-profit health care providers
increased to 30.9% (222.3 billion HUF), the local authorities had 43.8%, the central
government 22.7% and the non-profit sector 2.5% market share. We found the
largest increase of private for-profit health care providers in acute (from 0.8% in
2006 to 14.3 in 2009) and chronic care (from 1.1% in 2006 to 20.6% in 2009).
CONCLUSIONS: In line with the health policy objectives between 2006-2009, we
found a significant increase of private for-profit companies from health insurance
financing: they doubled their market share from 15.8% (2006) to 30.9% (2009). This
increase was attributed to the “functional” privatization of acute and chronic care
hospitals.
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OBJECTIVES: The aim of this review is to systematically summarize and assess the
existing economic evaluations of poison control centers (PCCs). METHODS: A lit-
erature search was performed to identify complete economic evaluations regard-
less of language or publication status by searching the following databases: Med-
line (via Pubmed), Embase, Centre for Reviews and Dissemination Databases,
Cochrane Library, Cochrane Central, metaRegister of Clinical Trials, LILACS, Sci-
ELO, ProQuest, Capes (Brazilian theses register) databases and abstracts at toxicol-
ogy congresses. Two reviewers assessed abstracts for inclusion and extracted the
data. Two experts assessed studies’ quality with a standardized tool (Drummond
2005). RESULTS:A total of 365 non-duplicated reports were identified, but only nine
met eligibility criteria. Five studies were published in the 1990s, and four were
published in the following decade. PCCs were compared to a scenario in which they
did not exist. Benefits were measured as potentially avoided healthcare charges.
Eight studies used cost-benefit analyses, and the other one used a cost-effective-
ness approach. Only two studies did not meet at least seven of 10 quality criteria.
Cost-benefit ratios ranged from 0.76 to 7.67, what means that each dollar spent on
poison centers saves almost US$ 8 in other medical spending. Incremental cost-
effectiveness ratios were US$ -12,000 for morbidity and -56,000 for mortality. These
results indicate that a significant cost savings is realized with each successful
outcome achieved by a poison center: US$ 12,000 in case of morbidity and US$
56,000 in case of mortality. CONCLUSIONS: Investment in PCCs appears to be a
rational public health policy. They could improve health care expenditure effi-
ciency and contribute to the sustainability of the health system. However, the
number of PCCs is decreasing in many countries.
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OBJECTIVES: To define the value medical services cost while conducting phar-
macoeconomic analysis. METHODS: A review of pharmacoeconomic researches of
5-alpha reductase inhibitors (5-ARI) application for treatment benign prostatic hy-
perplasia (BPH) has been conducted. The average prices for medical services for
care and treatment of BPH patients have been defined. The prices analysis of the
medical services Belarusian market in a urology specialty has been made. The
average prices comparison (in US dollars) of the actual medical services and prices
taken from medical literature has been done. RESULTS: The foreign medical liter-
ature review of using the 5-ARI for BPH patients shows the considerable economic
expenses because of an acute urinary retention hospitalization and surgical treat-
ment necessity. The medical services cost in Belarus is considerably cheaper to
compare with the costs given by foreign researchers’ reviews. We have specified
three procedures giving the significant contribution to the above-stated discrepan-
cies: the urologist examination cost in the USA 9 times exceeds the similar proce-
dure in our country (47,9$ versus 5$), transurethral resection (TURP) performance is
5 times (793$ versus 159$) and 1 day hospitalization cost without operative inter-
ventions and anesthesia is 364 times (4809$ versus 13,2$) more. CONCLUSIONS:
Hospital services and the medical staff work high cost in western countries allows
proving economically out-patient application of expensive treatment methods.
The end-points choice of the events demanding hospitalizations is not optimum at
making pharmacoeconomic researches in Belarus because of the low contribution
in hospital expenses versus the drug therapy cost. A complex approach with inte-
gration of several economic analyses is required to introduce new expensive inno-
vative drugs on the Belarusian pharmaceutical market.
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OBJECTIVES: After people living with HIV (PLWH) start on highly active antiretro-
viral therapy (HAART), rates of hospitalization for PLWH’s declined, but continued
still occurred at high levels. The increased prevalence of tobacco use among PLWH
and paucity of current data provide the rationale to study if tobacco use might
affect cost and clinical benefits of HAART among PLWH.METHODS:A decision-tree
model guided our assessment of the impact of tobacco on costs and effectiveness of
HAART by race/ethnicity. Using a payer perspective, the probabilities related with
smoke habit for racial group (African-Americans, Caribbeans, Hispanics, Cauca-
sians) were extracted from our prior tobacco study (n560) along with the number
of hospitalizations. This information along with hospital bed/day costs, provided
by Jackson Memorial Hospital’s patient accounting system, was used to estimate
the impact of the tobacco with a 1-year time frame. Results were express as cost per
hospitalizations related to smoking diseases (HRSD) RESULTS: Among patients
receiving antiretroviral therapy, our data indicated that smoking contributed a
$480,029 additional cost/year, with an average of $6,234/HRSD and an incremental
cost of $ 4,750 compared to non-smokers in the same treatment group. In the
Non-HAART Group, the incremental cost for smokers was $2,064,469, with an av-
erage of $8,054/HRSD and an incremental cost of $7,486. When racial group were
evaluated for smoking habit, the average costs for Hispanics receiving HAART was
$10,975/HRSD. African Americans despite the high cost reported for the total group
had an average cost of $8011/HRSD.CONCLUSIONS: In PLWH receiving HAART, our
analysis indicated that the benefits of HAART were negatively impacted by tobacco
use and costs are increased in the smokers in both the HAART and Non-HAART
groups. The data also indicated that focusing tobacco prevention efforts on minor-
ities may maximize effectiveness in terms of disease prevention and cost reduc-
tion.
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OBJECTIVOS:A un con un precio alto, la vacuna de VPH se ha asegura do una rápida
inclusión en los programas nacionales de inmunización (PNI) en economías avan-
zadas y emergentes. Por el contrario, otras vacunas nuevas, han encontrado una
aceptación más lenta en economías emergentes. El objetivo de esta investigación
es comparar el acceso al mercado de esta vacuna con los de las vacunas contra el
neumococo y la del Hib, con el fin de entender los criterios subyacentes en la
exitosa aceptación de una vacuna. METODOLOGÍAS: Cinco países de Latina
América fueron considerados en este estudio. Todos los países participaron en un
debate nacional de al menos dos de las vacunas sobre la inclusión en el PNI. Se
recopilaron los siguientes datos: fecha de autorización comercial y de inclusión en
el PNI, precio, restricciones de acceso y fuentes de financiación. Se llevó a cabo una
revisión cualitativa de la literatura y de las publicaciones de los Ministerios de
Salud de estos países para hacer un estudio comparativo de las tres vacunas.
RESULTADOS: Nuestro análisis muestra en todos los países una clara diferencia
entre la financiación del VPH y de las otras vacunas, con poca consistencia en el
razonamiento económico y político. Por ejemplo, los altos costos se citan como
barrera al acceso, sin embargo las poblaciones incluidas en los programas de va-
cunación del VPN son más grandes que en los países industrializados.
CONCLUSIONES: Los factores adicionales que influyen en la aceptación de una
vacuna varían dependiendo de los actores principales del debate nacional. Políti-
camente, las voces de los activistas contra el cáncer pueden aumentar la percep-
ción del valor social de una vacuna en particular. Estos factores son muy impor-
tantes y van más allá de la evaluación económica del proceso de inclusión de
vacunas en los PNIs.
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